William Blair Investment Management LLC Takes $188.07 Million Position in argenex SE $ARGX

William Blair Investment Management LLC purchased a new stake in shares of argenex SE (NASDAQ:ARGX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 223,666 shares of the company’s stock, valued at approximately $188,071,000. William Blair Investment Management LLC owned approximately 0.36% of argenex at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Capital World Investors raised its holdings in argenex by 0.4% in the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after acquiring an additional 8,422 shares during the period. M&T Bank Corp increased its holdings in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the period. Wellington Management Group LLP increased its holdings in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the period. Bank of America Corp DE boosted its position in shares of argenex by 1.9% during the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock valued at $252,525,000 after acquiring an additional 6,259 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after acquiring an additional 250,278 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Price Performance

ARGX opened at $806.46 on Friday. The company has a market cap of $49.90 billion, a price-to-earnings ratio of 35.91, a price-to-earnings-growth ratio of 1.28 and a beta of 0.46. The firm has a 50 day simple moving average of $767.17 and a 200 day simple moving average of $815.87. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. As a group, analysts expect that argenex SE will post 25.27 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ARGX shares. HC Wainwright boosted their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Oppenheimer reduced their target price on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Royal Bank Of Canada reduced their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,017.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.